Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm phase 3 study of bexarotene capsules in relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy
CTR20243921Phase 3Active
- Sponsor
- Minophagen Pharmaceutical Co., Ltd.
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bexarotene in cutaneous T-cell lymphoma (CTCL), sponsored by Minophagen Pharmaceutical Co., Ltd.. Started Feb 2025; status: active.
02
Drugs
bexarotene
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on CTR20243921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243921.